Insmed Incorporated
INSM
Rang in aandelen
#1117
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aandeelprijs
$95.40
Marktkapitalisatie
$20.83B
Verandering (1 dag)
0.12%
Verandering (1 jaar)
-43.18%
Land
US
Handel Insmed Incorporated (INSM)
Categorie
Healthcare
Winst voor Insmed Incorporated (INSM)
Winst in Jun 2026 TTM: $-869.11M
Volgens de meest recente financiële verslagen van Insmed Incorporated bedraagt de huidige winst van het bedrijf $-869.11M. In 2023 behaalde het bedrijf een winst van $-747.01M, een daling ten opzichte van de winst van 2022, die $-480.15M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Insmed Incorporated van 2000 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-869.11M | -4.50% |
| 2024 | $-910.07M | 21.83% |
| 2023 | $-747.01M | 55.58% |
| 2022 | $-480.15M | 10.02% |
| 2021 | $-436.41M | 49.10% |
| 2020 | $-292.69M | 15.43% |
| 2019 | $-253.56M | -21.76% |
| 2018 | $-324.08M | 67.98% |
| 2017 | $-192.92M | 9.51% |
| 2016 | $-176.18M | 46.62% |
| 2015 | $-120.15M | 34.13% |
| 2014 | $-89.58M | 56.35% |
| 2013 | $-57.29M | 38.48% |
| 2012 | $-41.37M | -30.66% |
| 2011 | $-59.66M | 838.70% |
| 2010 | $-6.36M | -105.35% |
| 2009 | $118.83M | -858.45% |
| 2008 | $-15.67M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-36.42M | -2.02% |
| 2001 | $-37.17M | -53.34% |
| 2000 | $-79.66M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -706.93% |
US
|
|
| $-3.09B | 255.19% |
US
|
|
| $-4.02B | 362.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -324.44% |
NL
|
